Literature DB >> 11753986

Ovarian epithelial carcinoma tyrosine phosphorylation, cell proliferation, and ezrin translocation are stimulated by interleukin 1alpha and epidermal growth factor.

Z Chen1, A Fadiel, Y Feng, K Ohtani, T Rutherford, F Naftolin.   

Abstract

BACKGROUND: Ezrin is a member of the ezrin, radixin, and moesin family. These proteins are membrane-actin cross-linking proteins. Furthermore, ezrin is an important signal transduction protein that undergoes phosphorylation and translocation on stimulation by growth factors. Ezrin phosphorylation and translocation are thought to be correlated with cell motility, invasion, and carcinoma metastasis. Recently, the authors reported that an ezrin antisense phosphorothionate could significantly inhibit endometrial carcinoma cells' penetration in the Matrigel membrane cancer invasion assay. In the current study, the authors measured ezrin content in clinical ovarian epithelial carcinoma (OVCA) specimens and cell lines and investigated whether interleukin (IL)-1alpha and epidermal growth factor (EGF) induce an invasive phenotype in OVCA cells via ezrin phosphorylation and translocation.
METHODS: Twenty-five normal ovary, 25 primary OVCA, 21 metastatic OVCA tissue (7 in omentum, 16 in ascites), and 3 OVCA cell lines were collected for Western blot detection of ezrin content. The OVCA cell line SKOV3 was treated with IL-1alpha or EGF. Indirect immunofluorescence staining followed by confocal laser scanning and double-staining electron microscopic immunohistochemistry were used to investigate changes in the intracellular distribution of ezrin and cell morphology after IL-1alpha or EGF treatment. The content of ezrin was measured by Western blotting and analyzed by the National Institutes of Health Image computer program. Immunoprecipitation and Western blot techniques were used for ezrin phosphorylation studies. Genistein was used to block tyrosine phosphorylation.
RESULTS: (1) Ezrin was overexpressed in OVCA, with the highest values in metastases. (2) Interleukin-1alpha and EGF significantly increased OVCA tyrosine phosphorylation, ezrin translocation, and cell growth. (3) These effects were abolished by treatment with the tyrosine kinase inhibitor, genistein. (4) Treatment with IL-1alpha or EGF induced an invasive phenotype, i.e., membrane ruffling, and process formation.
CONCLUSIONS: High expression and activation of ezrin appear to be related to OVCA metastatic behavior. Interleukin-1alpha and EGF may regulate OVCA invasive behavior by activating ezrin tyrosine phosphorylation, translocation, and cancer cell proliferation. The authors' results may partially explain why OVCA patients with positive macrophage colony stimulating factor (a chemoattractant of IL-1alpha secreting monocytes) or EGF receptors (c-erb B-2) have a poor prognosis. Copyright 2001 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11753986     DOI: 10.1002/1097-0142(20011215)92:12<3068::aid-cncr10149>3.0.co;2-5

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  25 in total

1.  Autoantibody biomarkers identified by proteomics methods distinguish ovarian cancer from non-ovarian cancer with various CA-125 levels.

Authors:  Aykan A Karabudak; Julie Hafner; Vivekananda Shetty; Songming Chen; Angeles Alvarez Secord; Michael A Morse; Ramila Philip
Journal:  J Cancer Res Clin Oncol       Date:  2013-09-03       Impact factor: 4.553

2.  The cytoskeletal protein ezrin regulates EC proliferation and angiogenesis via TNF-alpha-induced transcriptional repression of cyclin A.

Authors:  Raj Kishore; Gangjian Qin; Corinne Luedemann; Evelyn Bord; Allison Hanley; Marcy Silver; Mary Gavin; Young-sup Yoon; David Goukassian; David Goukassain; Douglas W Losordo
Journal:  J Clin Invest       Date:  2005-06-16       Impact factor: 14.808

Review 3.  Rationale and clinical experience with epidermal growth factor receptor inhibitors in gynecologic malignancies.

Authors:  Ami P Vaidya; Aric D Parnes; Michael V Seiden
Journal:  Curr Treat Options Oncol       Date:  2005-03

4.  Increase in ezrin expression from benign to malignant breast tumours.

Authors:  Daphne Gschwantler-Kaulich; Camilla Natter; Stefan Steurer; Ingrid Walter; Almut Thomas; Mohamed Salama; Christian F Singer
Journal:  Cell Oncol (Dordr)       Date:  2013-10-16       Impact factor: 6.730

5.  Expression of interleukin-1 (IL-1) ligands system in the most common endometriosis-associated ovarian cancer subtypes.

Authors:  Mamadou Keita; Paul Bessette; Manuella Pelmus; Youssef Ainmelk; Aziz Aris
Journal:  J Ovarian Res       Date:  2010-01-28       Impact factor: 4.234

6.  Epidermal growth factor-induced cellular invasion requires sphingosine-1-phosphate/sphingosine-1-phosphate 2 receptor-mediated ezrin activation.

Authors:  K Alexa Orr Gandy; Mohamad Adada; Daniel Canals; Brittany Carroll; Patrick Roddy; Yusuf A Hannun; Lina M Obeid
Journal:  FASEB J       Date:  2013-04-29       Impact factor: 5.191

7.  Comparative proteomic study of two closely related ovarian endometrioid adenocarcinoma cell lines using cIEF fractionation and pathway analysis.

Authors:  Lan Dai; Chen Li; Kerby A Shedden; David E Misek; David M Lubman
Journal:  Electrophoresis       Date:  2009-04       Impact factor: 3.535

Review 8.  Activated epidermal growth factor receptor in ovarian cancer.

Authors:  Laurie G Hudson; Reema Zeineldin; Melina Silberberg; M Sharon Stack
Journal:  Cancer Treat Res       Date:  2009

9.  Molecular targets for tumour progression in gastrointestinal stromal tumours.

Authors:  N Koon; R Schneider-Stock; M Sarlomo-Rikala; J Lasota; M Smolkin; G Petroni; A Zaika; C Boltze; F Meyer; L Andersson; S Knuutila; M Miettinen; W El-Rifai
Journal:  Gut       Date:  2004-02       Impact factor: 23.059

10.  The role of the membrane cytoskeleton cross-linker ezrin in medulloblastoma cells.

Authors:  Hirokatsu Osawa; Christian A Smith; Young Shin Ra; Paul Kongkham; James T Rutka
Journal:  Neuro Oncol       Date:  2008-12-16       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.